Last edition
News about "Hart-Scott-Rodino Antitrust Improvements Act "
Incyte to Acquire Vega Therapeutics, Expanding Hematology Portfolio
Incyte has agreed to acquire Vega Therapeutics, expanding its hematology portfolio into bleeding disorders with the addition of VGA039, a phase 3 investigational monoclonal antibody for von Willebrand disease. The deal includes USD 1.25 billion upfront and up to USD 750 million in additional payments upon achievement of sales milestones.
Hart-Scott-Rodino Antitrust Improvements Act | 09/06/2026 | By News Bureau
Novartis Announces Expiration of HSR Waiting Period of Regulus Therapeutics Tender Offer
Novartis announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock.
Hart-Scott-Rodino Antitrust Improvements Act | 24/06/2025 | By Darshana | 185
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy